Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy

Gady Har‐el; Tuvia Hadar; Karl Segal; Rudy Levy; Jack Sidi

doi:10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3

Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy

Gady Har‐el^*, Tuvia Hadar, Karl Segal, Rudy Levy, Jack Sidi

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well‐differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high‐grade malignancies and below those of low‐grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice. Cancer 57:1613–1617, 1986.

Original language	English
Pages (from-to)	1613-1617
Number of pages	5
Journal	Cancer
Volume	57
Issue number	8
DOIs	https://doi.org/10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3
State	Published - 15 Apr 1986

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3

Cite this

@article{07641a4e24d54cf4999b5e759283f68a,

title = "Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy",

abstract = "Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well‐differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high‐grade malignancies and below those of low‐grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice. Cancer 57:1613–1617, 1986.",

author = "Gady Har‐el and Tuvia Hadar and Karl Segal and Rudy Levy and Jack Sidi",

year = "1986",

month = apr,

day = "15",

doi = "10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3",

language = "אנגלית",

volume = "57",

pages = "1613--1617",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy

AU - Har‐el, Gady

AU - Hadar, Tuvia

AU - Segal, Karl

AU - Levy, Rudy

AU - Sidi, Jack

PY - 1986/4/15

Y1 - 1986/4/15

N2 - Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well‐differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high‐grade malignancies and below those of low‐grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice. Cancer 57:1613–1617, 1986.

AB - Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well‐differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high‐grade malignancies and below those of low‐grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice. Cancer 57:1613–1617, 1986.

UR - http://www.scopus.com/inward/record.url?scp=0022627413&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3

DO - 10.1002/1097-0142(19860415)57:8<1613::AID-CNCR2820570829>3.0.CO;2-3

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0022627413

SN - 0008-543X

VL - 57

SP - 1613

EP - 1617

JO - Cancer

JF - Cancer

IS - 8

ER -

Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this